Browse HAS1

Summary
SymbolHAS1
Namehyaluronan synthase 1
Aliases HAS; HA synthase 1; hyaluronate synthase 1; hyaluronic acid synthase 1; HuHAS1
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Multi-pass membrane protein
Domain -
Function

Catalyzes the addition of GlcNAc or GlcUA monosaccharides to the nascent hyaluronan polymer. Therefore, it is essential to hyaluronan synthesis a major component of most extracellular matrices that has a structural role in tissues architectures and regulates cell adhesion, migration and differentiation. This is one of the isozymes catalyzing that reaction. Also able to catalyze the synthesis of chito-oligosaccharide depending on the substrate (By similarity).

> Gene Ontology
 
Biological Process GO:0000271 polysaccharide biosynthetic process
GO:0001667 ameboidal-type cell migration
GO:0005976 polysaccharide metabolic process
GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0010761 fibroblast migration
GO:0010762 regulation of fibroblast migration
GO:0010764 negative regulation of fibroblast migration
GO:0016051 carbohydrate biosynthetic process
GO:0030198 extracellular matrix organization
GO:0030203 glycosaminoglycan metabolic process
GO:0030212 hyaluronan metabolic process
GO:0030213 hyaluronan biosynthetic process
GO:0030336 negative regulation of cell migration
GO:0033692 cellular polysaccharide biosynthetic process
GO:0034637 cellular carbohydrate biosynthetic process
GO:0036119 response to platelet-derived growth factor
GO:0036120 cellular response to platelet-derived growth factor stimulus
GO:0040013 negative regulation of locomotion
GO:0042698 ovulation cycle
GO:0043062 extracellular structure organization
GO:0044262 cellular carbohydrate metabolic process
GO:0044264 cellular polysaccharide metabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0044849 estrous cycle
GO:0045226 extracellular polysaccharide biosynthetic process
GO:0046379 extracellular polysaccharide metabolic process
GO:0048511 rhythmic process
GO:0051271 negative regulation of cellular component movement
GO:0085029 extracellular matrix assembly
GO:1903510 mucopolysaccharide metabolic process
GO:2000146 negative regulation of cell motility
Molecular Function GO:0008194 UDP-glycosyltransferase activity
GO:0016757 transferase activity, transferring glycosyl groups
GO:0016758 transferase activity, transferring hexosyl groups
GO:0050501 hyaluronan synthase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-2142850: Hyaluronan biosynthesis and export
R-HSA-2142845: Hyaluronan metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
Summary
SymbolHAS1
Namehyaluronan synthase 1
Aliases HAS; HA synthase 1; hyaluronate synthase 1; hyaluronic acid synthase 1; HuHAS1
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HAS1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolHAS1
Namehyaluronan synthase 1
Aliases HAS; HA synthase 1; hyaluronate synthase 1; hyaluronic acid synthase 1; HuHAS1
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HAS1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHAS1
Namehyaluronan synthase 1
Aliases HAS; HA synthase 1; hyaluronate synthase 1; hyaluronic acid synthase 1; HuHAS1
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HAS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3050.381
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4980.407
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1630.749
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.5090.0307
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.3210.323
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.7340.342
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2670.686
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2560.841
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.9840.516
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.520.394
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.120.179
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6590.0546
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HAS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHAS1
Namehyaluronan synthase 1
Aliases HAS; HA synthase 1; hyaluronate synthase 1; hyaluronic acid synthase 1; HuHAS1
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HAS1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHAS1
Namehyaluronan synthase 1
Aliases HAS; HA synthase 1; hyaluronate synthase 1; hyaluronic acid synthase 1; HuHAS1
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HAS1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HAS1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHAS1
Namehyaluronan synthase 1
Aliases HAS; HA synthase 1; hyaluronate synthase 1; hyaluronic acid synthase 1; HuHAS1
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HAS1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHAS1
Namehyaluronan synthase 1
Aliases HAS; HA synthase 1; hyaluronate synthase 1; hyaluronic acid synthase 1; HuHAS1
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HAS1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHAS1
Namehyaluronan synthase 1
Aliases HAS; HA synthase 1; hyaluronate synthase 1; hyaluronic acid synthase 1; HuHAS1
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HAS1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHAS1
Namehyaluronan synthase 1
Aliases HAS; HA synthase 1; hyaluronate synthase 1; hyaluronic acid synthase 1; HuHAS1
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HAS1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.